SG11202101814RA - Compositions of cxcr4 inhibitors and methods of preparation and use - Google Patents

Compositions of cxcr4 inhibitors and methods of preparation and use

Info

Publication number
SG11202101814RA
SG11202101814RA SG11202101814RA SG11202101814RA SG11202101814RA SG 11202101814R A SG11202101814R A SG 11202101814RA SG 11202101814R A SG11202101814R A SG 11202101814RA SG 11202101814R A SG11202101814R A SG 11202101814RA SG 11202101814R A SG11202101814R A SG 11202101814RA
Authority
SG
Singapore
Prior art keywords
compositions
preparation
methods
cxcr4 inhibitors
cxcr4
Prior art date
Application number
SG11202101814RA
Inventor
Karel Marie Joseph Brands
Original Assignee
X4 Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by X4 Pharmaceuticals Inc filed Critical X4 Pharmaceuticals Inc
Publication of SG11202101814RA publication Critical patent/SG11202101814RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202101814RA 2018-08-31 2019-08-30 Compositions of cxcr4 inhibitors and methods of preparation and use SG11202101814RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862726010P 2018-08-31 2018-08-31
US16/215,963 US10548889B1 (en) 2018-08-31 2018-12-11 Compositions of CXCR4 inhibitors and methods of preparation and use
PCT/US2019/049065 WO2020047410A1 (en) 2018-08-31 2019-08-30 Compositions of cxcr4 inhibitors and methods of preparation and use

Publications (1)

Publication Number Publication Date
SG11202101814RA true SG11202101814RA (en) 2021-03-30

Family

ID=69230180

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101814RA SG11202101814RA (en) 2018-08-31 2019-08-30 Compositions of cxcr4 inhibitors and methods of preparation and use

Country Status (13)

Country Link
US (4) US10548889B1 (en)
EP (1) EP3843720A4 (en)
JP (1) JP2021535146A (en)
KR (1) KR20210095118A (en)
CN (1) CN112839649A (en)
AU (1) AU2019328530A1 (en)
BR (1) BR112021003467A2 (en)
CA (1) CA3110735A1 (en)
EA (1) EA202190377A9 (en)
IL (1) IL281082A (en)
MX (1) MX2021002180A (en)
SG (1) SG11202101814RA (en)
WO (1) WO2020047410A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
JP6864296B2 (en) 2015-12-14 2021-04-28 エックス4 ファーマシューティカルズ, インコーポレイテッド How to treat cancer
DK3393468T3 (en) 2015-12-22 2022-12-19 X4 Pharmaceuticals Inc Methods for treating an immunodeficiency disease
WO2017177230A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN109641838A (en) 2016-06-21 2019-04-16 X4 制药有限公司 CXCR4 inhibitor and application thereof
JP7084624B2 (en) 2016-06-21 2022-06-15 エックス4 ファーマシューティカルズ, インコーポレイテッド CXCR4 inhibitor and its use
EP3471727B1 (en) 2016-06-21 2020-12-09 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
US10548889B1 (en) * 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US11878009B2 (en) * 2019-09-10 2024-01-23 Great Novel Therapeutics Biotech & Medicals Corporation Anticancer combination of chidamide and celecoxib salts
CN115515585A (en) * 2020-03-10 2022-12-23 X4 制药有限公司 Methods for treating neutropenia
AU2022360035A1 (en) * 2021-10-07 2024-04-18 X4 Pharmaceuticals, Inc. Synthesis of mavorixafor and intermediates thereof
WO2023107689A1 (en) * 2021-12-09 2023-06-15 X4 Pharmaceuticals, Inc. Methods for treating primary immunodeficiency
WO2023240259A1 (en) * 2022-06-10 2023-12-14 X4 Pharmaceuticals, Inc. Treatments for conditions involving increased il-6 levels

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4933447A (en) 1987-09-24 1990-06-12 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US6001826A (en) 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9200245D0 (en) 1992-01-07 1992-02-26 British Bio Technology Compounds
US5235056A (en) 1992-04-22 1993-08-10 Ciba-Geigy Corporation Substituted 1-hydroxy-2,6-diaryl-4-piperidone ketals and polymer compositions stabilized therewith
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
WO1997009976A2 (en) 1995-09-01 1997-03-20 Washington University Method of reducing neurotoxic injury with zinc chelators
CA2249401A1 (en) 1996-03-22 1997-09-25 The Dupont Merck Pharmaceutical Company Novel asymmetric synthesis of r-.alpha.-propyl-piperonyl amine and its analogs
AU740603B2 (en) 1997-06-02 2001-11-08 Janssen Pharmaceutica N.V. (imidazol-5-yl)methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
AU8576098A (en) 1997-07-25 1999-02-16 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
KR20010015639A (en) 1997-09-30 2001-02-26 스즈키 다다시 Sulfonyl derivatives
GB9726229D0 (en) 1997-12-12 1998-02-11 Zeneca Ltd Resolution of chiral amines
KR20010032841A (en) 1997-12-19 2001-04-25 다케다 야쿠힌 고교 가부시키가이샤 Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative
US6607799B1 (en) 1998-10-15 2003-08-19 3M Innovative Properties Company Surgical dressing with delivery system and method of manufacture
US6635278B1 (en) 1998-12-15 2003-10-21 Gilead Sciences, Inc. Pharmaceutical formulations
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
CZ20013421A3 (en) 1999-03-24 2002-03-13 Anormed Inc. Heterocyclic compounds binding chemokine receptors
US6245799B1 (en) 1999-11-08 2001-06-12 American Home Products Corp [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
US6602872B1 (en) 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
US6683192B2 (en) 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
PE20020354A1 (en) 2000-09-01 2002-06-12 Novartis Ag HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS
AU2001293551B2 (en) 2000-09-15 2007-08-23 Anormed Inc. Chemokine receptor binding heterocyclic compounds
AU9156901A (en) 2000-09-15 2002-03-26 Anormed Inc Chemokine receptor binding heterocyclic compounds
ES2269465T3 (en) 2000-09-15 2007-04-01 Anormed Inc HETEROCICLICAL COMPOUNDS OF UNION TO CHEMIOQUINE RECEPTORS.
CZ20031910A3 (en) 2000-12-11 2003-12-17 Tularik Inc. Compound exhibiting CXCR3 antagonistic activity and pharmaceutical preparation
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
PT1389617E (en) 2001-04-27 2007-04-30 Zenyaku Kogyo Kk Heterocyclic compound and antitumor agent containing the same as active ingredient
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
ATE538785T1 (en) 2001-07-31 2012-01-15 Genzyme Global S A R L METHOD FOR MOBILIZING PROCURSIONS/STEM CELLS
US7169750B2 (en) 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
US8178123B2 (en) 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
US20030055876A1 (en) * 2001-08-29 2003-03-20 Aravinda Korala Printing web content from self-service kiosks
CN101353324A (en) 2001-09-12 2009-01-28 阿诺麦德股份有限公司 Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
EP1465889B1 (en) * 2001-12-21 2017-03-22 Genzyme Corporation Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7491544B2 (en) 2002-05-20 2009-02-17 New York University Chiral piperidine and quinucledine ligands
CN1674929B (en) 2002-08-14 2013-07-17 赛伦斯治疗公司 Use of protein kinase N beta
JP4666256B2 (en) 2002-12-10 2011-04-06 小野薬品工業株式会社 Nitrogen-containing heterocyclic compound and pharmaceutical use thereof
KR20070087266A (en) 2003-04-03 2007-08-28 세마포르 파머슈티컬즈, 아이엔씨. Pi-3 kinase inhibitor prodrugs
EP1613613B1 (en) 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
AU2004232361A1 (en) 2003-04-22 2004-11-04 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7501518B2 (en) 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
EP1644363B1 (en) 2003-05-30 2012-02-22 Gemin X Pharmaceuticals Canada Inc. Triheterocyclic compounds, compositions, and methods for treating cancer
US7173015B2 (en) 2003-07-03 2007-02-06 The Trustees Of The University Of Pennsylvania Inhibition of Syk kinase expression
US7498346B2 (en) 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
RU2006136381A (en) * 2004-03-15 2008-04-27 Анормед, Инк. (Ca) METHOD FOR PRODUCING AN ANTAGONIST CXCR4
CA2561718A1 (en) 2004-04-13 2005-10-27 Icagen, Inc. Polycyclic pyridines as potassium ion channel modulators
DE102004021716A1 (en) 2004-04-30 2005-12-01 Grünenthal GmbH Substituted imidazo [1,2-a] pyridine compounds and drugs containing substituted imidazo [1,2-a] pyridine compounds
LT2612862T (en) 2004-05-13 2017-01-25 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
MX2007001514A (en) 2004-08-02 2007-03-27 Smithkline Beecham Corp Chemical compounds.
TW200619217A (en) 2004-08-16 2006-06-16 Smithkline Beecham Corp Chemical compounds
WO2006026703A2 (en) 2004-09-02 2006-03-09 Smithkline Beecham Corporation Chemical compounds
WO2006036816A2 (en) 2004-09-24 2006-04-06 Smithkline Beecham Corporation Chemical compounds
TW200619206A (en) 2004-09-29 2006-06-16 Anormed Inc Chemokine-binding heterocyclic compound salts, and methods of use thereof
EP1856135B1 (en) 2005-01-19 2009-12-09 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
WO2006096444A2 (en) 2005-03-04 2006-09-14 Smithkline Beecham Corporation Chemical compounds
PL2757099T3 (en) 2005-05-12 2018-02-28 Abbvie Bahamas Limited Apoptosis promoters
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
DE602006015966D1 (en) 2005-07-08 2010-09-16 Siemens Healthcare Diagnostics METHOD FOR PREDICTING AND MONITORING AN IMMEDIATE RESPONSE TO CANCER THERAPY
JP2009500451A (en) 2005-07-11 2009-01-08 スミスクライン ビーチャム コーポレーション Pyranopyridine compound
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
CN101277981B (en) 2005-08-02 2014-07-09 英尼奥斯欧洲有限公司 Diene polymerisation
AU2006280945A1 (en) 2005-08-19 2007-02-22 Genzyme Corporation Methods to enhance chemotherapy
WO2007027999A2 (en) 2005-08-31 2007-03-08 Smithkline Beecham Corporation Chemical compounds
EP1931645B1 (en) 2005-10-07 2014-07-16 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
CN103626742B (en) 2005-11-01 2017-04-26 塔格根公司 Bi-aryl meta-pyrimidine inhibitors of kinases
US8168783B2 (en) 2005-11-18 2012-05-01 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonists and use thereof
AR063656A1 (en) 2005-11-30 2009-02-11 Schering Corp COMPOSITIONS THAT INCLUDE A COMBINATION OF ANTAGONISTS OF CCR5 AND CXCR4
ES2612196T3 (en) 2005-12-13 2017-05-12 Incyte Holdings Corporation Pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines substituted with heteroaryl as Janus kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي PI-3 Kinase inhibitors and methods of their use
WO2007087548A2 (en) 2006-01-25 2007-08-02 Smithkline Beecham Corporation Chemical compounds
TW200738711A (en) 2006-01-25 2007-10-16 Smithkline Beecham Corp Chemical compounds
GB0605786D0 (en) 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
RU2439074C2 (en) 2006-04-26 2012-01-10 Ф. Хоффманн-Ля Рош Аг THIENO[3,2-d]PYRIMIDINE DERIVATIVE AS PHOSPHATIDYL INOSITOL-3-KINASE (PI3K) INHIBITOR
US20070259040A1 (en) 2006-05-01 2007-11-08 Cherukuri S R Novel triptan formulations and methods for making them
MX2008014296A (en) 2006-06-12 2009-03-06 Pfizer Prod Inc Pharmaceuticals.
TWI482772B (en) 2006-08-21 2015-05-01 Astrazeneca Ab Compositions, suitable for oral administration, comprising a triazolo(4,5-d)pyrimidin derivate
SI2526933T1 (en) 2006-09-22 2015-07-31 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
EP3023422A1 (en) 2007-03-12 2016-05-25 YM BioSciences Australia Pty Ltd Phenyl amino pyrimidine compounds and uses thereof
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
EP2155747B1 (en) 2007-05-10 2012-10-24 GE Healthcare Limited Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors
PE20090717A1 (en) 2007-05-18 2009-07-18 Smithkline Beecham Corp QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
WO2009026251A1 (en) 2007-08-17 2009-02-26 The General Hospital Corporation Detecting ions and measuring ion concentrations
US9101628B2 (en) 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection
MX2010010012A (en) 2008-03-11 2010-10-20 Incyte Corp Azetidine and cyclobutane derivatives as jak inhibitors.
EP2254597A4 (en) 2008-03-20 2012-04-18 Carolus Therapeutics Inc Methods of treatment using anti-mif antibodies
AU2009228034A1 (en) 2008-03-28 2009-10-01 Altiris Therapeutics Chemokine receptor modulators
WO2009151910A2 (en) 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
JP2010016628A (en) 2008-07-03 2010-01-21 Canon Inc Image processing device and image processing method
PT2364314E (en) 2008-12-09 2014-06-09 Gilead Sciences Inc Modulators of toll-like receptors
US9119790B2 (en) 2009-09-28 2015-09-01 Zenbury International Limited Pharmaceutical composition
US20110290821A1 (en) 2010-05-28 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-viral compositions and methods for administration
CA2706292A1 (en) 2010-05-28 2011-11-28 Pharmascience Inc. A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
US9155723B2 (en) 2010-06-28 2015-10-13 The General Hospital Corporation Anti-CXCR4 as a sensitizer to cancer therapeutics
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
US9267934B2 (en) 2010-10-26 2016-02-23 University Of South Alabama Methods and compositions for ameliorating pancreatic cancer
AU2011336397B2 (en) 2010-12-03 2016-12-15 Emory University Chemokine CXCR4 receptor modulators and uses related thereto
WO2012078633A2 (en) 2010-12-07 2012-06-14 Philadelphia Health And Education Corporation, D/B/A Drexel University College Of Medicene Methods of inhibiting metastasis from cancer
CN107699585A (en) 2010-12-09 2018-02-16 宾夕法尼亚大学董事会 The purposes of the T cell treating cancer of Chimeric antigen receptor modification
AU2012206945B2 (en) 2011-01-11 2015-02-19 Dimerix Bioscience Pty Ltd Combination therapy
BR112013029482A2 (en) 2011-05-16 2016-08-09 Genzyme Corp use of cxr4 antagonists
AR087364A1 (en) 2011-07-29 2014-03-19 Pf Medicament ANTI-CXCR4 ANTIBODY AND ITS USE FOR CANCERES DETECTION AND DIANOSTIC
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013106732A1 (en) 2012-01-12 2013-07-18 Gilead Sciences, Inc. Pharmaceutical compositions and methods for their preparation
US20150301058A1 (en) 2012-11-26 2015-10-22 Caris Science, Inc. Biomarker compositions and methods
US10064826B2 (en) 2013-03-15 2018-09-04 Navinta, Llc Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process
EP3473299A1 (en) 2013-06-05 2019-04-24 Salk Institute for Biological Studies Vitamin d receptor agonists to treat diseases involving cxcl12 activity
WO2015019284A2 (en) 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition of cxcr4 signaling in cancer immunotherapy
PT3650014T (en) 2013-08-27 2021-12-27 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
AU2014318614B2 (en) 2013-09-12 2021-01-07 Dana-Farber Cancer Institute Inc. Methods for evaluating and treating Waldenstrom's macroglobulinemia
US20150273033A1 (en) 2013-11-05 2015-10-01 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
WO2015143092A1 (en) 2014-03-18 2015-09-24 The Research Foundation For The State University Of New York Therapeutic agent for treating tumors
JP6701088B2 (en) 2014-03-19 2020-05-27 インフィニティー ファーマシューティカルズ, インコーポレイテッド Heterocyclic compounds for use in the treatment of PI3K-gamma mediated disorders
EP3157921A1 (en) 2014-06-23 2017-04-26 Dr. Reddy's Laboratories Ltd. Substituted imidazo[1,2-a]pyridine compounds useful for the treatment of pain
PL3169341T3 (en) 2014-07-16 2019-12-31 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
KR20170105514A (en) 2014-12-12 2017-09-19 커먼웰쓰 사이언티픽 앤 인더스트리알 리서치 오거니제이션 Dislodgement and release of hsc using alpha 9 integrin antagonist and cxcr4 antagonist
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
CA2989144A1 (en) 2015-06-12 2016-12-15 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
EP3350183A1 (en) 2015-09-14 2018-07-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US10379661B2 (en) 2015-09-25 2019-08-13 Samsung Electronics Co., Ltd. Coordinate measuring apparatus and coordinate measuring system having the same
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
JP6864296B2 (en) 2015-12-14 2021-04-28 エックス4 ファーマシューティカルズ, インコーポレイテッド How to treat cancer
DK3393468T3 (en) 2015-12-22 2022-12-19 X4 Pharmaceuticals Inc Methods for treating an immunodeficiency disease
CA3010617A1 (en) 2016-01-22 2017-07-27 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017177230A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
KR102548385B1 (en) 2016-04-14 2023-06-28 크리에티브이 마이크로테크, 인크. Methods of using pd-l1 expression in treatment decisions for cancer therapy
CN109641838A (en) 2016-06-21 2019-04-16 X4 制药有限公司 CXCR4 inhibitor and application thereof
EP3471727B1 (en) 2016-06-21 2020-12-09 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
JP7084624B2 (en) 2016-06-21 2022-06-15 エックス4 ファーマシューティカルズ, インコーポレイテッド CXCR4 inhibitor and its use
CN110996952A (en) 2017-06-21 2020-04-10 X4 制药有限公司 Methods for treating cancer
US20210349099A1 (en) 2017-11-07 2021-11-11 X4 Pharmaceuticals, Inc. Cancer biomarkers and methods of use thereof
JP2021506838A (en) 2017-12-19 2021-02-22 エックス4 ファーマシューティカルズ, インコーポレイテッド Acyclic CXCR4 Inhibitors and Their Use
WO2019200223A1 (en) 2018-04-13 2019-10-17 X4 Pharmaceuticals, Inc. Cancer serum biomarkers and methods of use thereof
US10548889B1 (en) * 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use

Also Published As

Publication number Publication date
EA202190377A1 (en) 2021-07-22
US20200253953A1 (en) 2020-08-13
KR20210095118A (en) 2021-07-30
US11672793B2 (en) 2023-06-13
BR112021003467A2 (en) 2021-05-18
IL281082A (en) 2021-04-29
US20220008410A1 (en) 2022-01-13
WO2020047410A1 (en) 2020-03-05
JP2021535146A (en) 2021-12-16
EP3843720A4 (en) 2022-07-27
CA3110735A1 (en) 2020-03-05
EA202190377A9 (en) 2021-08-09
US11045461B2 (en) 2021-06-29
US10548889B1 (en) 2020-02-04
US20240058322A1 (en) 2024-02-22
MX2021002180A (en) 2021-09-14
CN112839649A (en) 2021-05-25
AU2019328530A1 (en) 2021-04-01
EP3843720A1 (en) 2021-07-07

Similar Documents

Publication Publication Date Title
IL281082A (en) Compositions of cxcr4 inhibitors and methods of preparation and use
GB2582482B (en) CASZ compositions and methods of use
IL277889A (en) Oligonucleotide compositions and methods of use thereof
IL291933A (en) Oligonucleotide compositions and methods of use thereof
SG11202010131QA (en) Oligonucleotide compositions and methods of use thereof
SG11202111386UA (en) Oligonucleotide compositions and methods of use thereof
GB2582100B (en) CAS12C Compositions and methods of use
IL279475A (en) Ectonucleotidase inhibitors and methods of use thereof
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL276135A (en) Compositions and methods of use
IL287768A (en) Kcnt1 inhibitors and methods of use
IL287751A (en) Kcnt1 inhibitors and methods of use
ZA201906169B (en) Synthekine compositions and methods of use
IL287973A (en) Acss2 inhibitors and methods of use thereof
SG11202106585UA (en) Polishing compositions and methods of using same
GB202105087D0 (en) Microbial compositions and methods of use
EP3606493A4 (en) Dental cement compositions and methods of use
SG11202106584QA (en) Polishing compositions and methods of using same
EP3691646A4 (en) Inhalable composition of clofazimine and methods of use
IL285247A (en) Enhanced nitrate compositions and methods of use
GB202319843D0 (en) CAS13-based compositions and methods of use thereof
IL264854A (en) Spt5 inhibitors and methods of use thereof
IL282533A (en) Oligosaccharide compositions and methods of use thereof
IL287797A (en) Oligosaccharide compositions and methods of use
ZA202007107B (en) Compositions comprising pcsk9-binding molecules and methods of use